Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Eur J Clin Pharmacol

Retrieve available abstracts of 13 articles:
HTML format

Single Articles

    January 2021
  1. GU X, Zhu M, Sheng C, Yu S, et al
    Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding model.
    Eur J Clin Pharmacol. 2021 Jan 10. pii: 10.1007/s00228-020-03080.
    PubMed     Abstract available

    August 2020
  2. YOON HY, Ahn MH, Yee J, Lee N, et al
    Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis.
    Eur J Clin Pharmacol. 2020;76:1053-1058.
    PubMed     Abstract available

    August 2019
  3. BAFTIU A, Lima MH, Svendsen K, Larsson PG, et al
    Safety aspects of antiepileptic drugs-a population-based study of adverse effects relative to changes in utilisation.
    Eur J Clin Pharmacol. 2019;75:1153-1160.
    PubMed     Abstract available

    January 2019
  4. SHI L, Zhu M, Li H, Wen Z, et al
    SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients.
    Eur J Clin Pharmacol. 2019 Jan 28. pii: 10.1007/s00228-019-02633.
    PubMed     Abstract available

  5. MANOHARAN A, Kumar AS, Sreedevi A, Sathishkannan AD, et al
    HLA-B*5701 and HLA-B*5801 in an Indian patient with anti-epileptics induced cutaneous adverse drug reactions.
    Eur J Clin Pharmacol. 2019 Jan 4. pii: 10.1007/s00228-018-02618.

    November 2018
  6. LIN WW, Li XW, Jiao Z, Zhang J, et al
    Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
    Eur J Clin Pharmacol. 2018 Nov 19. pii: 10.1007/s00228-018-2600.
    PubMed     Abstract available

    April 2018
  7. MEI S, Feng W, Zhu L, Li X, et al
    Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.
    Eur J Clin Pharmacol. 2018 Apr 17. pii: 10.1007/s00228-018-2440.
    PubMed     Abstract available

  8. WANG P, Lin XQ, Cai WK, Xu GL, et al
    Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis.
    Eur J Clin Pharmacol. 2018;74:433-442.
    PubMed     Abstract available

    March 2018
  9. RODRIGUES C, Chhun S, Chiron C, Dulac O, et al
    A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.
    Eur J Clin Pharmacol. 2018 Mar 21. pii: 10.1007/s00228-018-2444.
    PubMed     Abstract available

    February 2018
  10. KHELOUFI F, Default A, Perrouty B, Blin O, et al
    Perampanel-associated self-harm ideation after dosage increase.
    Eur J Clin Pharmacol. 2018;74:243-244.

    January 2018
  11. MORATH B, Green K, Zaradzki M, Heid J, et al
    Subtherapeutic valproic acid plasma concentrations under concomitant dipyrone therapy in an epilepsy patient-a case report.
    Eur J Clin Pharmacol. 2018 Jan 23. pii: 10.1007/s00228-018-2417.

  12. XU S, Liu L, Chen Y, Liu M, et al
    Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.
    Eur J Clin Pharmacol. 2018 Jan 16. pii: 10.1007/s00228-018-2414.
    PubMed     Abstract available

    April 2017
  13. BAFTIU A, Landmark CJ, Rusten IR, Feet SA, et al
    Erratum to: Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-A pharmacoepidemiological study and clinical implications.
    Eur J Clin Pharmacol. 2017 Apr 7. doi: 10.1007/s00228-017-2252.

Thank you for your interest in scientific medicine.

AMEDEO Epilepsy is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.